Abstracts tagged "Antibodies"

Abstract Number: 635 • 2015 ACR/ARHP Annual Meeting
Seronegative Sjögren’s Syndrome Is Associated with a Higher Frequency of Patient-Reported Neuropathic Pain: An Analysis of the Sjögren’s International Collaborative Clinical Alliance Cohort
Alan N. Baer¹ and Julius Birnbaum², ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Patients with Sjögren’s syndrome (SS) and negative SSA/SSB serology (ie. seronegative SS) have phenotypic characteristics different than seropositive ones, and thus may constitute a…
Abstract Number: 3112 • 2015 ACR/ARHP Annual Meeting
Incidence of Anti-Drug Antibodies in Rheumatoid Arthritis Patients Treated with Adalimumab, Etanercept, or Infliximab in a Real-World Setting
RJ Moots¹, Ricardo Xavier², Chi Chiu Mok³, Mahboob U Rahman⁴, Wen-Chan Tsai⁵, Mustafa Al Maini⁶, Karel Pavelka⁷, Ehab Mahgoub⁸, Sameer Kotak⁹, Joan Korth-Bradley¹⁰, Ronald Pedersen¹¹, Linda Mele⁸, Qi Shen⁸ and Bonnie Vlahos⁸, ¹Department of Musculoskeletal Biology, University of Liverpool, Liverpool, United Kingdom, ²Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ³Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ⁴Perelman School of Medicine, University of Pennsylvania, Philadephia, PA, ⁵Kaohsiung Medical University, Kaohsiung, Taiwan, ⁶Rheumatology, Allergy and Clinical Immunology Division, Mafraq Hospital, Abu Dhabi, United Arab Emirates, ⁷Charles University, Prague, Czech Republic, ⁸GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ⁹Global Health and Value, Pfizer, New York, NY, ¹⁰GIPB- Clinical Sciences, Pfizer, Collegeville, PA, ¹¹Department of Biostatistics, Pfizer, Collegeville, PA
Background/Purpose: Treatment with biologics can elicit unwanted immune responses such as antidrug antibodies (ADA), which may decrease their clinical efficacy and increase adverse events. However,…
Abstract Number: 809 • 2015 ACR/ARHP Annual Meeting
Patients with SLE Who Are Anti-Factor Xa IgG Positive Are Less Likely to Have Atherosclerotic Plaque
Claire-Louise Murphy¹, Sara Croca¹, Bahar Artim-Esen², Laura Hanns³, Charis Pericleous¹, Thomas McDonnell¹, Yiannis Ioannou⁴, David A. Isenberg¹, Anisur Rahman¹ and Ian Giles⁵, ¹Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ²Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³Rheumatology, Arthritis Research UK Centre for Adolescent Rheumatology, UCL Division of Medicine, London, United Kingdom, ⁴Rayne Institute, Arthritis Research UK Centre for Adolescent Rheumatology, UCL Division of Medicine, London, United Kingdom, ⁵Rayne Intitiute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom
Background/Purpose: Patients with SLE have an increased risk of cardiovascular disease (CVD), which is not fully explained by traditional risk factors and may be mediated…
Abstract Number: 823 • 2015 ACR/ARHP Annual Meeting
Anti-IFI16 Antibodies in Scleroderma Are Associated with Digital Gangrene
Zsuzsanna McMahan¹, Ami A. Shah², Dhananjay Vaidya³, Fredrick M. Wigley⁴, Antony Rosen⁵ and Livia Casciola-Rosen⁶, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Medicine, School of Medicine, Johns Hopkins, Baltimore, MD, ⁴Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Mason Lord Bldg Ctr Tower, Johns Hopkins University, School of Medicine, Baltimore, MD, ⁶Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Our aim was to examine and confirm the association between anti-IFI16 antibodies and clinical features of scleroderma. Methods: Sera from a discovery sample…
Abstract Number: 1151 • 2015 ACR/ARHP Annual Meeting
The Proteomic Profile of Histological Samples Derived from a Surgical Mouse Model of Osteoarthritis Reveals an Unexpected Mode of Action for the Anti-Aggrecanase-2 Monoclonal Antibody CRB0017
Gianfranco Caselli¹, Riccardo Chiusaroli², Michela Visintin³, Tiziana Piepoli², Ornella Letari², Adriana Grotti², Marco Lanza², Antonella De Palma⁴, Dario di Silvestre⁴, Pierluigi Mauri⁴ and Lucio Claudio Rovati², ¹Pharmacology & Toxicology, Rottapharm Biotech Srl, Monza, Italy, ²Rottapharm Biotech Srl, Monza, Italy, ³Rottapharm Biotech Srl, Trieste, Italy, ⁴Institute for Biomedical Technologies - CNR, Segrate, Italy
Background/Purpose : CRB0017 is a novel therapeutic monoclonal antibody that recognizes the spacer domain of aggrecanase-2, a key enzyme in the degradation of extracellular matrix…
Abstract Number: 1366 • 2015 ACR/ARHP Annual Meeting
Natural Antibodies, Not B Cells, Contribute to Acute Cell Death-Induced Inflammation
Hiroshi Kataoka, Rheumatology and Clinical Immunology, Sapporo City General Hospital, Sapporo, Japan
Background/Purpose: Alarmins, such as uric acid, released from dying cells activate inflammasomes and mediate dead cell-induced inflammation (Ref.). Since it is remains unknown whether or…
Abstract Number: 1772 • 2015 ACR/ARHP Annual Meeting
Anti-Pentraxin 3 Antibodies Ameliorate Disease Manifestations and Lupus-like Nephritis in New Zealand Black/New Zealand White F1 Mice
Mariele Gatto¹, Nicola Bassi¹, Anna Ghirardello¹, Roberto Luisetto¹, Silvano Bettio¹, Luca Iaccarino¹, Leonardo Punzi² and Andrea Doria², ¹Department of Medicine-DIMED, University of Padova, Padova, Italy, ²Department of Medicine - DIMED, University of Padova, Padova, Italy
Background/Purpose: Pentraxin 3 (PTX3) is an acute-phase protein released by different cell types including renal epithelial cells and immune-competent cells. PTX3 is able to either…
Abstract Number: 1858 • 2015 ACR/ARHP Annual Meeting
Serum Tartrate Resistant Acid Phosphatase (TRAP) Levels Are Decreased and Associated with Anti-Maa Antibodies in Systemic Lupus Erythematosus (SLE) Patients
Kathleen Borghoff¹, Andy Hollins², Michael J. Duryee¹, Ted R. Mikuls², Zhixin Zhang³, Kaihong Su⁴, Michelene Hearth-Holmes⁵ and Geoffrey M. Thiele⁶, ¹Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ⁴Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ⁵Division of Rheumatology, University of Nebraska College of Medicine and VA Nebraska Western Iowa Health Care System, Omaha, NE, ⁶Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Previous studies have shown that patients with systemic lupus erythematosus (SLE) are prone to systemic osteoporosis, bone loss and fracture. Paradoxically, previous studies…
Abstract Number: 2019 • 2015 ACR/ARHP Annual Meeting
Serum Biomarkers of Inflammatory Arthritis in First Degree Relatives of Patients with Rheumatoid Arthritis and Their Association with Lifestyle Risk Factors
Jamie C Sergeant and RA-MAP Consortium, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom
Background/Purpose: Rheumatoid factor (RF), anti-cyclic citrullinated peptide antibodies (anti-CCP) and C-reactive protein (CRP) are known serum biomarkers of inflammatory arthritis (IA) and have potential predictive…
Abstract Number: 2057 • 2015 ACR/ARHP Annual Meeting
Antibodies to Infliximab in Remicade-Treated Rheumatic Patients Show Identical Reactivity Towards Biosimilars
Begoña Ruiz-Argüello¹, Ainara Maguregui¹, Ainhoa Ruiz del Agua¹, Dora Pascual-Salcedo², Ana Martínez², Teresa Jurado³, Chamaida Plasencia⁴, Alejandro Balsa⁵, Francisca Llinares-Tello⁶, José Rosas⁷, Nerea Torres¹, Antonio Martínez¹ and Daniel Nagore¹, ¹R&D, Progenika-Grifols, Derio, Spain, ²Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ³Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, ⁴Rheumatology Unit, La Paz University Hospital-Rheumatology, Madrid, Spain, ⁵Rheumatology, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ⁶Clinical Analysis, Hospital Marina Baixa, Clinical Analysis, Villajoyosa, Spain, ⁷Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain
Background/Purpose: Infliximab (IFX) is the most immunogenic of anti-TNFα drugs available to treat patients with rheumatic diseases. The recent approval of the first infliximab biosimilars in…
Abstract Number: 2362 • 2015 ACR/ARHP Annual Meeting
Rituximab in the Treatment of Jo-1 Antibody-Associated Antisynthetase Syndrome: Anti-Ro52 Positivity As a Marker for Severity and Treatment Response
Jutta Bauhammer¹, Norbert Blank², Hanns-Martin Lorenz³, Regina Max⁴, Dietmar Krause⁵ and Christoph Fiehn¹, ¹ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany, ²Dept. of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, ³Department of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, ⁴Dept. of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, ⁵Dept. of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany
Background/Purpose: Rituximab (RIX) has successfully been used for the treatment of severe Jo-1 antibody-associated antisynthetase syndrome (Jo-1 ASS). The aim of this retrospective study was…
Abstract Number: 405 • 2015 ACR/ARHP Annual Meeting
Anti-C1q Antibodies As Potential Diagnostic and Prognostic Biomarkers in Juvenile Systemic Lupus Erythematosus
Thaschawee Arkachaisri^1,2, Justin Hung Tiong Tan¹, Manasita Tanya¹, Sook Fun Hoh³, Lena Das⁴ and Jing Yao Leong^5,6, ¹Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ²Paediatrics, Duke-NUS Graduate Medical School, Singapore, Singapore, ³Nursing, KK Women's and Children's Hospital, Singapore, Singapore, ⁴Dept of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ⁵Duke-National University of Singapore Graduate Medical School, Singapore, Singapore, ⁶SingHealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore
Background/Purpose: Anti-C1q antibodies (AC1q) were shown to strongly correlate with the occurrence and activity of lupus nephritis in adult SLE. Data of the antibodies in…
Abstract Number: 2367 • 2015 ACR/ARHP Annual Meeting
Risk of Malignancy in Dermatomyositis with Anti-CADM-140/ Melanoma Differentiation- Associated Gene 5 Autoantibody
Shinji Sato¹, Takayoshi Kurabayashi¹, Sho Sasaki², Yasushi Koyama², Shinichi Nogi³, Naofumi Chinen¹, Chiho Yamada¹ and Yasuo Suzuki¹, ¹Internal Medicine/ Rheumatology, Tokai University School of Medicine, Isehara, Japan, ²Internal Medicine/Rheumatology, Tokai University School of Medicine, Isehara, Japan, ³Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
Background/Purpose: Anti-CADM-140/ Melanoma Differentiation-Associated Gene 5 (MDA5) antibody is found specifically in patients with dermatomyositis (DM). This autoantibody is associated with clinically amyopathic DM (CADM)…
Abstract Number: 483 • 2015 ACR/ARHP Annual Meeting
Antibody to Malondialdehyde-Acetaldehyde (MAA) Adducts Serve As Biomarkers of Treatment Response in Rheumatoid Arthritis
Ted R. Mikuls¹, Brian Coburn¹, Harlan Sayles², Fang Yu³, Mary Brophy⁴, James R. O'Dell¹, Lynell W. Klassen⁵ and Geoffrey M. Thiele¹, ¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Public Health, University of Nebraska Medical Center, Omaha, NE, ⁴VA Boston Heathcare System, Boston, MA, ⁵Dept of Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Previous reports have demonstrated that malondialdehyde-acetaldehyde (MAA) adducts are produced as a byproduct of oxidative stress and lipid peroxidation and are expressed in…
Abstract Number: 2376 • 2015 ACR/ARHP Annual Meeting
Clinical Features in Dermatomyositis Patients with Novel Autoantibody to Small Ubiquitin-like Modifier Activating Enzymes (Anti-SAE Antibody) and Relationship to Interstitial Lung Disease: A Systematic Review of 29 Cases
Sirada Panupattanapong¹, Jessica Sun² and Kevin Baszis¹, ¹Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, ²Pediatric, Division of Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO
Background/Purpose: Anti-SAE antibody is a novel myositis-specific antibody first described in 2007. SAE is an enzyme that facilitates sumoylation, leading to the formation of stable…

« Previous Page
1
…
3
4
5
6
7
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].